SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is a hot topic following its announcement of a strategic manufacturing partnership designed to scale production of its fingerprinting drug screening reader and reduce costs. The market is heavily divided, with many anticipating explosive gains due to the stock's low float, while others express significant concern over recent share dilution from a private placement with warrants. This has created extremely volatile trading activity, as bullish momentum traders clash with short-sellers over the stock's immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is a key topic as it actively positions itself for the substantial Rural Health Transformation Program, aiming to modernize rural healthcare with its virtual care network and AI-driven solutions. Investors are vocal, with some passionately highlighting the company's global leadership and significant undervaluation, expecting a major turnaround, while others voice deep frustration over past stock performance and current management's perceived shortcomings. Recent discussions also revolve around strategic partnerships, such as the TytoCare integration for at-home care, as potential catalysts.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Widespread speculation about a potential SpaceX initial public offering is driving significant market conversation and creating considerable buzz within the aerospace sector. This anticipation is fueling active community discussion around related companies positioned as 'SpaceX IPO plays' or partners, notably highlighting firms involved in upcoming Falcon 9 missions. However, alongside the excitement, some investors are raising cautionary flags about speculative mentions and the legitimacy of certain 'SPACEX CRYPTO' references.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention for its expanding anticoagulation pipeline, highlighted by recent acquisitions and significant progress on its lead candidate, tecarfarin, including manufacturing readiness and a collaboration with Abbott. This "quiet expansion" is sparking community interest, with many anticipating a breakout given its low float and regulatory designations. However, skepticism persists among some regarding the company's financial stability and potential dilution.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is a hot topic following a substantial $600 million financing boost and the looming 1-for-30 reverse stock split, which has sparked intense debate among investors. While many are optimistic about strong Q4 delivery numbers for the Polestar 4 and new Google Gemini AI integration, community sentiment remains sharply divided on whether operational improvements can finally overcome persistent skepticism about the stock's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus recommendation of "Hold" by the eleven brokerages that are presently covering the stock, MarketBeat Ratings...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS...

Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 4,607.1% during the second quarter, according to its most recent 13F filing with the Securities...

Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS

Panagora Asset Management Inc. acquired a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing...

Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume Increase - What's Next?

Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume Increase - Here's What Happened...

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been given an average recommendation of "Hold" by the eleven analysts that are currently covering the firm, MarketBeat...

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH...

Bailard Inc. Buys New Shares in Astria Therapeutics, Inc. $ATXS

Bailard Inc. acquired a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Current Price	$13.09
Prev Close	$12.99
Open	$13.00
Dividend Yield	0.00%
50-Day Moving Average	$12.66
Beta	1.18
Avg. Volume	1.06M
PE Ratio	-6.09

52-Week High	$13.29
52-Week Low	$3.56
Market Capitalization	$747.24M
EPS (Annual)	-$1.68
Price to Book	5.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ATXS
Astria Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATXS News

ATXSAstria Therapeutics Inc